首页> 外文期刊>Hepatitis Monthly >Treatment of HCV Patients Before and After Renal Transplantation
【24h】

Treatment of HCV Patients Before and After Renal Transplantation

机译:HCV患者在肾移植前后的治疗

获取原文
           

摘要

Context: Patients with end-stage renal disease can easily acquire a hepatitis C virus (HCV) infection via several ways. An HCV infection is difficult to treat after renal transplantation due to the conflicting actions of immunosuppressant therapy to maintain the function of the transplanted kidney and viricidal interferon (IFN) or ribavirin (RBV) treatment. Antiviral therapy requires great caution to avoid the complex and potentially fatal pharmacological effects. In this review, we examined clinical challenges and potential solutions for this specific scenario. Evidence Acquisitions: We searched Pubmed (NLM), LISTA (EBSCO), Web of Science (TS). The management of patients on waiting list, the indications and regimens about treatment were studied. Results: More than forty papers about this topic were found, including seven small clinical trials. International consensus has been reached to test patients awaiting renal transplantation. HCV detection after renal transplantation warrants careful consideration of when to initiate antiviral therapy. Treatment will begin immediately if deteriorating liver function increases the risk for loss of renal function. The choice of regimen depends on the patient's renal function and is individualized under close observation. The immunosuppressive regimen will be adjusted accordingly before antiviral therapy is initiated. Conclusions: The effects of modified antiviral therapy on these patients varies because of individual characteristics and disease state, and also because of the difficulty associated with conducting a large clinical trial to obtain statistically sound conclusions. The management before transplantation is important and when antiviral therapy needs to start, careful consideration of risks and benefits is needed before initiating this type of treatment. Implication for health policy/practice/research/medical education: There is no consensus on the management of HCV patients before and after renal transplantation. This review focuses on the recent information about these special situations in order to bring out some common opinions on how to manage such patients. Please cite this paper as: Du L, Tang H. Treatment of HCV Patients Before and After Renal Transplantation. Hepat Mon. 2011;11(11):880-6.
机译:背景:患有终末期肾脏疾病的患者可以通过多种方式轻松获得丙型肝炎病毒(HCV)感染。 HCV感染在肾移植后难以治疗,原因是免疫抑制剂治疗维持移植肾的功能与杀伤性干扰素(IFN)或利巴韦林(RBV)治疗相抵触。抗病毒治疗需要格外小心,以避免复杂和潜在的致命药理作用。在这篇综述中,我们研究了针对这种特定情况的临床挑战和潜在解决方案。证据获取:我们搜索了Pubmed(NLM),LISTA(EBSCO),Web of Science(TS)。研究了候诊病人的管理,治疗的适应症和治疗方案。结果:共发现40余篇有关该主题的论文,包括7项小型临床试验。已经达成国际共识以测试等待肾移植的患者。肾移植后的HCV检测值得仔细考虑何时开始抗病毒治疗。如果肝功能恶化增加肾功能丧失的风险,将立即开始治疗。方案的选择取决于患者的肾功能,并在密切观察下个性化。在开始抗病毒治疗之前,将相应地调整免疫抑制方案。结论:改良抗病毒治疗对这些患者的影响因个人特征和疾病状态而异,并且还因为进行大型临床试验来获得统计上可靠的结论所带来的困难。移植前的管理很重要,当需要开始抗病毒治疗时,在开始此类治疗之前需要仔细考虑风险和收益。对健康政策/实践/研究/医学教育的意义:在肾移植之前和之后,HCV患者的治疗尚无共识。这篇综述着重于有关这些特殊情况的最新信息,以期就如何治疗此类患者提出一些共识。请引用本文:Du L,Tang H.肾移植前后HCV患者的治疗。肝星期一2011; 11(11):880-6。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号